.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

OncLive Data Review: SABCS 2021

EP. 1: Dr. Spring on the Rationale for the AMEERA-1 Trial in ER+/HER2- Advanced Breast Cancer

February 1st 2022

Laura Spring, MD, discusses the rationale for the ongoing phase 1/2 AMEERA-1 trial in estrogen receptor–positive, HER2-negative advanced breast cancer.